Breaking News Instant updates and real-time market news.

AMGN

Amgen

$194.92

-0.48 (-0.25%)

14:06
09/29/19
09/29
14:06
09/29/19
14:06

Amgen announces new data evaluating novel investigational KRAS inhibitor

Amgen announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The data include the first evidence of anti-tumor activity reported in patients with colorectal cancer and appendiceal cancer, as well as previously presented non-small cell lung cancer findings. AMG 510 continues to be well-tolerated with no dose-limiting toxicities. The study enrolled 76 patients with KRAS G12C-mutant solid tumors. Data being presented at ESMO include a subset of 55 evaluable patients as of the July 2019 data cutoff, including CRC, appendiceal cancer and NSCLC patients from the Phase 1 study. Of the 55 patients, 29 had CRC. 12 patients with CRC received the target dose of 960 mg once daily and 10 remain on treatment. One patient in this dose cohort experienced a partial response and 10 had stable disease for a disease control rate of 92%. 13 of the evaluable patients with NSCLC received 960 mg, of which seven achieved a partial response at one or more timepoints and six achieved stable disease, for a disease control rate of 100%. Data across dosing cohorts also showed tumor responses in two evaluable patients with appendiceal cancer with one partial response and one experiencing stable disease. Among the 76 patients enrolled across treatment groups, 52 remain on treatment. The majority of treatment-related adverse events were grade 1 and 2. Only two TRAEs were grade 3. There were no grade 4 or higher TRAEs.

AMGN Amgen
$194.92

-0.48 (-0.25%)

09/19/19
09/19/19
NO CHANGE

Amgen management to meet with Oppenheimer
Meetings to be held in Europe on September 19-20 hosted by Oppenheimer.
09/20/19
09/20/19
NO CHANGE

Amgen management to meet with Oppenheimer
Meetings to be held in Europe on September 19-20 hosted by Oppenheimer.
09/24/19
GUGG
09/24/19
UPGRADE
Target $116
GUGG
Buy
Mirati Therapeutics upgraded to Buy ahead of KRAS G12C data at Guggenheim
Guggenheim analyst Michael Schmidt upgraded Mirati Therapeutics (MRTX) to Buy from Neutral with a $116 price target ahead of Phase 1 data expected to be reported in Q4 on the company's KRAS G12C inhibitor, MRTX849. While it is still uncertain how Mirati's drug compares to others in the class, particularly most advanced competitor Amgen's (AMGN) AMG 510, Schmidt sees the risk/reward of owning Mirati shares as skewed to the upside following clinical updates provided by Amgen at a recent conference. Assuming MRTX849 has a comparable clinical profile compared to AMG 510, the company will have an opportunity to participate in a potential $6.4B global market for KRAS G12C inhibitors, Schmidt tells investors.
09/27/19
FBCO
09/27/19
NO CHANGE
Target $115
FBCO
Outperform
Mirati Therapeutics price target lowered to $115 from $120 at Credit Suisse
Credit Suisse analyst Evan Seigerman maintained an Outperform rating on Mirati Therapeutics (MRTX) and lowered his price target to $115 from $120 following the interim data update from the company's only clinical stage KRAS inhibitor competitor from Amgen (AMGN), AMG 510. In a research note to investors, Seigerman says he believes Amgen's AMG 510 is more than six months ahead of MRTX849 and sees potential for the first-mover to capture significant share given the high unmet need. The analyst remains positive on both programs, but is taking a conservative view as he awaits interim MRTX849 data.

TODAY'S FREE FLY STORIES

TEL

TE Connectivity

$93.74

0.885 (0.95%)

07:45
10/22/19
10/22
07:45
10/22/19
07:45
Initiation
TE Connectivity initiated  »

TE Connectivity initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

MBRX

Moleculin Biotech

$1.07

-0.005 (-0.47%)

07:45
10/22/19
10/22
07:45
10/22/19
07:45
Hot Stocks
Moleculin Biotech raises Annamycin production »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

07:43
10/22/19
10/22
07:43
10/22/19
07:43
Earnings
Breaking Earnings news story on NextEra Energy Partners »

NextEra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Dec

AX

Axos Financial

$29.97

0.54 (1.83%)

07:43
10/22/19
10/22
07:43
10/22/19
07:43
Hot Stocks
Newbridge Securities enters five-year clearing agreement with Axos Clearing »

Newbridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 06

    Nov

  • 04

    Dec

  • 05

    Dec

CVA

Covanta

$17.06

0.31 (1.85%)

07:42
10/22/19
10/22
07:42
10/22/19
07:42
Downgrade
Covanta rating change  »

Covanta double downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

APH

Amphenol

$100.40

1.35 (1.36%)

07:42
10/22/19
10/22
07:42
10/22/19
07:42
Initiation
Amphenol initiated  »

Amphenol initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

MAIN

Main Street

$42.50

0.23 (0.54%)

07:41
10/22/19
10/22
07:41
10/22/19
07:41
Downgrade
Main Street rating change  »

Main Street downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$103.39

4.25 (4.29%)

, OPK

Opko Health

$2.12

0.03 (1.44%)

07:40
10/22/19
10/22
07:40
10/22/19
07:40
Recommendations
Ascendis Pharma, Opko Health, Pfizer analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$103.39

4.25 (4.29%)

OPK

Opko Health

$2.12

0.03 (1.44%)

PFE

Pfizer

$36.45

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Dec

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

, CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

07:40
10/22/19
10/22
07:40
10/22/19
07:40
Hot Stocks
Callon Petroleum files presentation highlighting benefits of Carrizo deal »

Callon Petroleum Company…

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 14

    Nov

  • 14

    Nov

BAND

Bandwidth

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Upgrade
Bandwidth rating change  »

Bandwidth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ARCC

Ares Capital

$18.70

0.14 (0.75%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Downgrade
Ares Capital rating change  »

Ares Capital downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FRPT

Freshpet

$49.68

0.05 (0.10%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Upgrade
Freshpet rating change  »

JPMorgan upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 19

    Nov

  • 20

    Nov

CHCO

City Holding

$79.30

1.94 (2.51%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Earnings
City Holding reports Q3 EPS $1.36, consensus $1.32 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCC

Owl Rock

$16.90

-0.08 (-0.47%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Downgrade
Owl Rock rating change  »

Owl Rock downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

, CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Hot Stocks
Paulson & Co. reiterates opposition to Carrizo deal »

Paulson & Co., as…

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 14

    Nov

  • 14

    Nov

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Hot Stocks
Lockheed Martin sees FY20 sales $62.0B, consensus $62.82B »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RVNC

Revance

$15.67

0.495 (3.26%)

07:37
10/22/19
10/22
07:37
10/22/19
07:37
Conference/Events
Revance management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 21

    Nov

AAOI

Applied Optoelectronics

$10.83

-0.02 (-0.18%)

07:37
10/22/19
10/22
07:37
10/22/19
07:37
Downgrade
Applied Optoelectronics rating change  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 09

    Dec

ZION

Zions Bancorp

$45.68

0.96 (2.15%)

07:36
10/22/19
10/22
07:36
10/22/19
07:36
Recommendations
Zions Bancorp analyst commentary  »

Zions Bancorp price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBIX

Ebix

$39.90

1.32 (3.42%)

07:35
10/22/19
10/22
07:35
10/22/19
07:35
Hot Stocks
Ebix facilitates $20B of premiums for Willis Accounting over last four years »

Ebix Europe announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

07:35
10/22/19
10/22
07:35
10/22/19
07:35
Earnings
Lockheed Martin raises FY19 EPS view to $21.55 from $20.85-$21.15 »

Raises FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

WBS

Webster Financial

$47.31

0.39 (0.83%)

07:35
10/22/19
10/22
07:35
10/22/19
07:35
Earnings
Webster Financial reports Q3 EPS $1.00, consensus $1.01 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

CNC

Centene

$45.83

-1.09 (-2.32%)

07:35
10/22/19
10/22
07:35
10/22/19
07:35
Conference/Events
Centene management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

KR

Kroger

$24.11

0.17 (0.71%)

, JBLU

JetBlue

$17.54

0.59 (3.48%)

07:35
10/22/19
10/22
07:35
10/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

KR

Kroger

$24.11

0.17 (0.71%)

JBLU

JetBlue

$17.54

0.59 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 10

    Nov

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

07:34
10/22/19
10/22
07:34
10/22/19
07:34
Hot Stocks
Kimberly-Clark provides update to 2018 Global Restructuring Program »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.